

Special Issue

Influence of Natural and/or Vaccine Immunity on the Dynamics of SARS-CoV-2

Message from the Guest Editor

Reports from South Africa, along with evidence that Omicron (BA.1) could cause reinfection, suggest that new waves of infection can occur in highly immune populations whose are immune due to a prior infection and/or vaccination. Other preliminary studies indicate that BA.2 can readily overcome the immunity provided by vaccination and/or infection with an earlier variant, although its real impact on the spread of the virus in a specific area remains elusive. With the emergence of these new variants of SARS-CoV-2, questions around the impact of a natural infection (old or recent) and different vaccine strategies on the spread of the epidemic need answering. We are pleased to invite you to reflect with us on this pressing issue. The aim of this Special Issue is the influence of natural and/or vaccine immunity on the dynamics of SARS-CoV-2. As part of the scope, the current status of the diagnosis of, therapeutics around, and vaccines for COVID-19 are of particular interest to *Vaccines*. We look forward to receiving your contributions.

Guest Editor

Dr. Chloé Dimeglio

Virology Laboratory, Toulouse University Hospital, 330 Avenue de Grande Bretagne 31059, 31300 Toulouse, France

Deadline for manuscript submissions

31 December 2024



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/116896

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).